Not Yet RecruitingPhase 2ACTRN12607000384459

To evaluate the efficacy of nasal oxytocin in the treatment of migraine headaches

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Nasal Oxytocin for the Treatment of Migraine Headaches

Sponsor

Trigemina, Inc

Enrollment

100 participants

Start Date

Sep 1, 2007

Study Type

Interventional

Conditions

migraine headache

Summary

Nasal oxytocin may be useful in preventing migraine attacks. The purpose of this study is to determine how well nasal oxytocin helps treat migraine attacks and the safety of nasal oxytocin and any side effects that may happen when it is given to migraine patients

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 65 Yearss

Plain Language Summary

Simplified for easier understanding

This study investigates To evaluate the efficacy of nasal oxytocin in the treatment of migraine headaches. It is looking for both men and women, aged 18 to 65 who have diagnosed with migraine according to IHS-criteria (see Appendix 1)Suffering from migraine > 1 yearAt least 1-6 attacks per month in each of the six.... People who are pregnant or breastfeeding individuals cannot take part. If you are interested, you may need to attend study visits and follow the research team's instructions.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

active drug: nasal oxytocin administered as one puff (100µL, 4IU) in each nostril at time 0, 5 minutes, 10 minutes and 15 minutes on Study Day 1

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000384459